Impact of low-value medications on quality of life, hospitalization and costs - A longitudinal analysis of patients living with dementia.
Alzheimer's disease
dementia
health care costs
health care resources
health-related quality of life
hospitalization
low-value care
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
19
01
2023
received:
18
10
2022
accepted:
22
01
2023
medline:
12
10
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
This study aimed to analyze the impact of low-value medications (Lvm), that is, medications unlikely to benefit patients but to cause harm, on patient-centered outcomes over 24 months. This longitudinal analysis was based on baseline, 12 and 24 months follow-up data of 352 patients with dementia. The impact of Lvm on health-related quality of life (HRQoL), hospitalizations, and health care costs were assessed using multiple panel-specific regression models. Over 24 months, 182 patients (52%) received Lvm at least once and 56 (16%) continuously. Lvm significantly increased the risk of hospitalization by 49% (odds ratio, confidence interval [CI] 95% 1.06-2.09; p = 0.022), increased health care costs by €6810 (CI 95% -707€-14,27€; p = 0.076), and reduced patients' HRQoL (b = -1.55; CI 95% -2.76 to -0.35; p = 0.011). More than every second patient received Lvm, negatively impacting patient-reported HRQoL, hospitalizations, and costs. Innovative approaches are needed to encourage prescribers to avoid and replace Lvm in dementia care. Over 24 months, more than every second patient received low-value medications (Lvm). Lvm negatively impact physical, psychological, and financial outcomes. Appropriate measures are needed to change prescription behaviors.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4520-4531Informations de copyright
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Berwick DM, Hackbarth AD. Eliminating waste in US Health Care. JAMA. 2012;307:1513-1516.
Ingvarsson S, Hasson H, von Thiele Schwarz U, et al. Strategies for de-implementation of low-value care-a scoping review. Implement Sci. 2022;17:73.
Shrank WH, Rogstad TL, Parekh N. Waste in the US Health Care System: estimated costs and potential for savings. Jama. 2019;322:1501-1509.
Verkerk EW, Tanke MAC, Kool RB, van Dulmen SA, Westert GP. Limit, lean or listen? A typology of low-value care that gives direction in de-implementation. Int J Qual Health Care. 2018;30:736-739.
Elshaug AG, Rosenthal MB, Lavis JN, et al. Levers for addressing medical underuse and overuse: achieving high-value health care. Lancet. 2017;390:191-202.
Mafi JN, Reid RO, Baseman LH, Hickey S, Totten M, Agniel D, et al. Trends in low-value health service use and spending in the us medicare fee-for-service program, 2014-2018. JAMA Netw Open. 2021;4:e2037328.
Korenstein D, Chimonas S, Barrow B, Keyhani S, Troy A, Lipitz-Snyderman A. Development of a conceptual map of negative consequences for patients of overuse of medical tests and treatments. JAMA Intern Med. 2018;178:1401-1407.
Schwartz AL, Landon BE, Elshaug AG, Chernew ME, McWilliams JM. Measuring low-value care in Medicare. JAMA Intern Med. 2014;174:1067-1076.
Brett J, Elshaug AG, Bhatia RS, Chalmers K, Badgery-Parker T, Pearson SA. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. Implement Sci. 2017;12:58.
Brett J, Zoega H, Buckley NA, Daniels BJ, Elshaug AG, Pearson SA. Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia. BMC Health Serv Res. 2018;18:1009.
Radomski TR, Decker A, Khodyakov D, et al. Development of a metric to detect and decrease low-value prescribing in older adults. JAMA Netw Open. 2022;5:e2148599.
Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. Age Ageing. 2017;46:33-39.
Kaczynski A, Michalowsky B, Eichler T, et al. Comorbidity in dementia diseases and associated health care resources utilization and cost. J Alzheimers Dis. 2019;68:635-646.
Mueller C, Molokhia M, Perera G, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. Exp Gerontol. 2018;106:240-245.
Platen M, Fleßa S, Rädke A, et al. Prevalence of low-value care and its associations with patient-centered outcomes in dementia. J Alzheimers Dis. 2021;83:1775-1787.
Platen M, Flessa S, Radke A, et al. Associations between low-value medication in dementia and healthcare costs. Clin Drug Investig. 2022;42:427-437.
Wohlgemuth A, Michalowsky B, Wucherer D, et al. Drug-related problems increase healthcare costs for people living with dementia. J Alzheimers Dis. 2020;73:791-799.
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden Of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125.
Wimo A, Guerchet M, Ali GC, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13:1-7.
Harrison SL, Kouladjian O'Donnell L, Milte R, et al. Costs of potentially inappropriate medication use in residential aged care facilities. BMC Geriatr. 2018;18:9.
Pagès A, Costa N, Mounié M, et al. Healthcare costs associated with potentially inappropriate medication prescribing detected by computer algorithm among older patients. Drugs Aging. 2022;39:367-375.
Thyrian JR, Fiß T, Dreier A, et al. Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials. 2012;13:56.
Calabrese P, Kessler J. Screening for cognitive impairment in dementia - the DemTect procedure. European Neuropsychopharmacology. 2000;10:369.
Thyrian JR, Eichler T, Michalowsky B, et al. Community-Dwelling people screened positive for dementia in primary care: a comprehensive, multivariate descriptive analysis using data from the delphi-study. J Alzheimers Dis. 2016;52:609-617.
Kessler J, Markowitsch HJ, Denzler P, Mini-Mental-Status-Test (MMST) [German Version]. 1 ed. Göttingen, Ger: Beltz Test GmbH; 1990.
Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H. The bayer activities of daily living scale (B-ADL). Dement Geriatr Cogn Disord. 1998;9(Suppl 2):20-26.
Gauggel S, Birkner B. Validität und reliabilität einer deutschen version der geriatrischen depressionsskala (GDS). Zeitschrift für Klinische Psychologie und Psychotherapie. 1999;28:18-27.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
World Health Organization. (1993). The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization. https://apps.who.int/iris/handle/10665/37108
Fiß T, Thyrian JR, Wucherer D, et al. Medication management for people with dementia in primary care: description of implementation in the DelpHi study. BMC Geriatr. 2013;13:121.
Michalowsky B, Eichler T, Thyrian JR, et al. Medication cost of persons with dementia in primary care in Germany. J Alzheimers Dis. 2014;42:949-958.
Deutsche Gesellschaft für Psychiatrie Psychotherapie und Nervenheilkunde und Deutsche Gesellschaft für Neurologie. S3-Leitlinie Demenzen. Springer-Verlag; 2017.
Holt S, Schmiedl S, Thürmann PA. Potenziell inadäquate Medikation für ältere Menschen. Dtsch Arztebl International. 2010;107:543-551.
Deutsche Gesellschaft für Innere Medizin e.V. Sammelband Initiative “Klug Entscheiden”. Deutsches Ärzteblatt. 2019;115.
Ware J Jr., Kosinski M, Keller SD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
Bock JO, Brettschneider C, Seidl H, et al. Calculation of standardised unit costs from a societal perspective for health economic evaluation. Gesundheitswesen. 2015;77:53-61.
Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics. 1998;13:487-497.
StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.
Patel R, Zhu L, Sohal D, et al. Use of 2015 beers criteria medications by older medicare beneficiaries. Consult Pharm. 2018;33:48-54.
Zimmermann T, Kaduszkiewicz H, van den Bussche H, et al. Potentially inappropriate medication in elderly primary care patients : a retrospective, longitudinal analysis. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:941-949.
Berry SD, Placide SG, Mostofsky E, et al. Antipsychotic and benzodiazepine drug changes affect acute falls risk differently in the nursing home. J Gerontol A Biol Sci Med Sci. 2016;71:273-278.
Chantanachai T, Taylor ME, Lord SR, et al. Risk factors for falls in community-dwelling older people with mild cognitive impairment: a prospective one-year study. PeerJ. 2022;10:e13484.
Badgery-Parker T, Pearson SA, Dunn S, Elshaug AG. Measuring hospital-acquired complications associated with low-value care. JAMA Intern Med. 2019;179:499-505.
Pohl-Dernick K, Meier F, Maas R, Schoffski O, Emmert M. Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list. BMC Health Serv Res. 2016;16:109.
Baicker K, Chandra A. Do we spend too much on health care? New England Journal of Medicine. 2020;383:605-608.
Geschke K, Fellgiebel A, Laux N, Schermuly I, Scheurich A. Quality of life in dementia: impact of cognition and insight on applicability of the SF-36. Am J Geriatr Psychiatry. 2013;21:646-654.
Kruger C, Schafer I, van den Bussche H, et al. Comparison of FORTA, PRISCUS and EU(7)-PIM lists on identifying potentially inappropriate medication and its impact on cognitive function in multimorbid elderly German people in primary care: a multicentre observational study. BMJ Open. 2021;11:e050344.
Wehling M. Drug therapy for older people : choosing wisely. Z Gerontol Geriatr. 2017;50:685-688.